V900323
Hydroxyurea
Vetec™, reagent grade, ≥98%
Synonym(s):
Hydroxycarbamide
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
NH2CONHOH
CAS Number:
Molecular Weight:
76.05
EC Number:
204-821-7
UNSPSC Code:
12352200
PubChem Substance ID:
Beilstein/REAXYS Number:
1741548
MDL number:
Assay:
≥98%
grade
reagent grade
product line
Vetec™
assay
≥98%
storage temp.
2-8°C
SMILES string
NC(=O)NO
InChI
1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChI key
VSNHCAURESNICA-UHFFFAOYSA-N
Gene Information
human ... RRM1(6240), RRM2(6241), RRM2B(50484)
Biochem/physiol Actions
Anti-neoplastic. Inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronization or cell death in S-phase.
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Hydroxyurea
signalword
Danger
hcodes
Hazard Classifications
Muta. 1B - Repr. 2
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Suchitra Natarajan et al.
Neoplasia (New York, N.Y.), 15(3), 263-280 (2013-03-13)
The non-histone chromatin binding protein high mobility group AT-hook 2 (HMGA2) is expressed in stem cells and many cancer cells, including tumor initiating cells, but not translated in normal human somatic cells. The presence of HMGA2 is correlated with advanced
Guido Finazzi et al.
British journal of haematology, 161(5), 688-694 (2013-04-12)
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia
Winfred C Wang et al.
Pediatrics, 132(4), 677-683 (2013-09-04)
In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care
Global Trade Item Number
| SKU | GTIN |
|---|---|
| V900323-100G | 04061833026205 |
| V900323-250G | 04061833026212 |